A study has cast doubt on the widely cited claim that antidepressant drugs such as SSRIs have few withdrawal symptoms, revealing that pharmaceutical industry funding could be skewing data to minimise adverse effects.
This story first appeared on leafie, view here
Author: Liam O’Dowd